Navigation Links
ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
Date:3/3/2009

Diagnostics and Therapeutics divisions.

2009 will be a pivotal year for ExonHit Therapeutics. Assuming successful clinical validation of EHT Dx21, its blood diagnostic test for Alzheimer's disease, the Company will put its first product on the market. Furthermore, assuming successful completion of the EHT 0202 Phase lla study, the Company will engage in out-licensing activities to support further development of this product in Alzheimer's disease.

2008 Consolidated financial results

Philippe Rousseau, Chief Financial Officer of ExonHit Therapeutics, said: "Our investment efforts in the clinical development of our lead compounds in both Diagnostics and Therapeutics will continue in the first half of 2009 whereas in the second part of the year, we are committed to invest in marketing to prepare for EHT Dx21's launch." He added: "Our financial situation remains healthy with more than 24 months of cash at the end of 2008 and a tool to strengthen our shareholder's equity, the warrant exercise period running until the end of June."

- Income Statement

Total revenues amount to EUR 4.2 million, a decrease of 22% compared to the EUR 5.4 million achieved in 2007. This decrease mainly comes from our Therapeutics activities as in 2007 we recognized a milestone payment in our strategic collaboration with Allergan in addition to the annual R&D payments.

Consolidated R&D revenues were EUR 4.2 million in 2008, down 21% compared to EUR 5.3 million in 2007. R&D revenues from grants decreased to EUR 0.01 million in 2008 from EUR 0.05 million in 2007.

R&D expenses have increased by 15% to EUR 9.9 million in 2008 compared to EUR 8.6 million in 2007, mainly as a result of increased expenses in clinical trials in both our therapeutics and diagnostics activities. In 2008, R&D revenues covered 43% of the Company's R&D expenses, as opposed to 62% in 200
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI)
2. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
3. Loic Maurel Joins Exonhit Therapeutics to Become CEO
4. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
5. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
6. ExonHit Appoints a New Management Board
7. ExonHit Therapeutics - 2007 Financial Results
8. ExonHit Builds A New Organisation
9. ExonHit and bioMerieux Amend Their Strategic Partnership
10. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
11. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... , June 26, 2015  SeraCare Life Sciences, ... manufacturers, today announced that it has signed a ... National Cancer Institute (NCI), part of the National ... positive controls for cancer assays.  The CRADA will ... accurately quantitate control DNA biosynthetics spiked into a ...
(Date:6/26/2015)... MUMBAI, India , June 26, 2015 ... a leading global IT services, consulting and business solutions ... Leader in Worldwide Life Sciences R&D Risk-Based Monitoring by ... MarketScape: Worldwide Life Science R&D Risk-Based Monitoring 2015 Vendor ... The report evaluated eight leading IT services vendors with ...
(Date:6/26/2015)... ... 26, 2015 , ... ReliantHeart, Inc. , an innovative supplier of advanced ... of the HeartAssist5® LVAD (HA5) to the 68th consecutive implant, there has been no ... in an LVAD is referred to as de novo thrombus. De novo thrombus can ...
(Date:6/25/2015)... ... 25, 2015 , ... Students entering the new Hemenway Hall ... each exclusively using filtered fume hoods that feature Erlab’s GreenFumeHood Filtration Technology ... hoods needed for their Organic, Inorganic, Analytical, and Physical Chemistry teaching laboratories. Each ...
Breaking Biology Technology:SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 2TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 4HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3This Summer Erlab Completes the Largest Installation of Filtered Fume Hoods in the World 2
... Dendreon Corporation (Nasdaq: DNDN ) management will host a conference call ... second quarter 2009 financial results. Access to the discussion may be obtained as ... 11:30 AM ET /8:30 AM PT, Date: ... (domestic) or +1-719-325-4873 (international), Webcast: www.dendreon.com (homepage and investor ...
... , , , PITTSBURGH, July 30 ... the three and six months ended June 30, 2009. , , ... Adjusted diluted EPS, which excludes the impact of certain purchase accounting items ... $0.65 for the three and six months ended June 30, 2009, compared to $0.20 ...
... a weakened strain of the malaria parasite that will be ... developed in collaboration with researchers from the US, Japan and ... Malaria kills more than one million people each year and ... of at least 35 million years of healthy, productive human ...
Cached Biology Technology:Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET 2Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 2Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 3Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 4Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 5Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 6Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 7Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 8Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 9Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 10Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 11Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 12Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 13Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 14Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 15Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 16Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 17Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 18First genetically engineered malaria vaccine to enter human trials 2
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
(Date:6/16/2015)... 16, 2015 Fingerprint Cards (FPC) raises ... it will amount to at least 340 MSEK to that ... rapid increase in market growth and orders received the revenue ... that revenue for 2015 will exceed 1,500 MSEK to an ... 2,200 MSEK. Due to receipt of orders of ...
(Date:6/11/2015)... June 11, 2015 Daon, a global ... that its IdentityX Mobile Authentication Platform v4.0 has ... Alliance is an industry consortium launched in 2013 ... simpler, stronger authentication.  In order to receive certification, ... rigorous series of tests that measure compliance and ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... Cold Spring Harbor, NY A rose by any ... confound scientists interested in understanding the chemical components of its ... That,s because in biology, an organism,s scientific (taxonomic) ... This data on the genetic, ecological, and agricultural particulars ...
... 31, 2012 WestPark Capital, Inc., a Los Angeles based ... non-exclusive engagement agreement with Alliqua, Inc.  During the term ... the company regarding business and finance, private and public ... its securities holders and provide introductions to investors. ...
... they do because large fish and urchins eat most of the ... has found that the greatest impact of all comes from an ... the journal Ecology Letters is the largest of its ... it was led by Associate Professor Alistair Poore, of the UNSW ...
Cached Biology News:New release of Web-based resource resolves confusion over plant names 2New release of Web-based resource resolves confusion over plant names 3WestPark Capital, Inc. Engaged By Alliqua, Inc. 2Grazing snails rule the waves 2
... 8 micro-bore tubes to 1 outflow ... tips, Rapid (several millisecond) solution change ... prevention , Solid construction 360, 250 ... For mounting on any micromanipulator Available ...
... (BTI-TN-5B1-4) derived from Trichoplusia ni egg ... be capable of expressing significantly higher ... to other insect cells. High Five ... time as adherent cultures- Quick adaptation into ...
... Racks are ideal for storage and transport ... polypropylene racks withstand extreme temperatures, making them ... may also be autoclaved for use in ... side accommodates 0.5ml microcentrifuge tubes, the other ...
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
Biology Products: